project id: TCGA-PRAD; case submitter id: TCGA-EJ-A8FU; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.94; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.44; rna integrity number: 7.8; age at index: 64; days to birth: -23472; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1949; age at diagnosis: 23472; ajcc clinical m: M0; ajcc clinical t: T3a; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 138.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 89; initial weight: 210.0; sample id: ba08195b-31cf-4bb1-a470-23740225c99d; sample submitter id: TCGA-EJ-A8FU-01A; portion id: 1de5e67a-ac3f-4c18-92c4-27ba1868c7ac; portion submitter id: TCGA-EJ-A8FU-01A-11; slide id: 454a95d5-d084-4f36-b1f1-32c6c23ab46e; slide submitter id: TCGA-EJ-A8FU-01A-01-TSA; percent lymphocyte infiltration: 6.0; percent monocyte infiltration: 0.0; percent necrosis: 1.0; percent neutrophil infiltration: 1.0; percent normal cells: 3.0; percent stromal cells: 77.0; percent tumor cells: 19.0; percent tumor nuclei: 60.0; section location: TOP;